Stocktube video
24/06/2011

Alliance Pharma CEO John Dawson says fundamentals remain intact

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: APH
Latest Price: 30.50p  (0,00%)
52-week High: 37.25p
52-week Low: 26.25p
Market Cap: 73.02M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Alliance Pharma
www.alliancepharma.co.uk

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

Pdf

Alliance Pharma shareholder Nigel Wray buys 200,000 more shares

15th Mar 2010, 4:29 pm Alliance Pharma shareholder Nigel Wray buys 200,000 more shares

Alliance Pharma (AIM: APH) announced that Nigel Wray has bought a further 200,000 shares in the company to take his holding to 24,519,995 shares, or 11.04% of the capital. He is still the group's second largest shareholder behind chief executive John Dawson.

Alliance Pharma (AIM: APH) last month completed the acquisition of Cambridge Laboratories. The deal, which adds 18 new prescription products to Alliance’s portfolio, is expedted to be significantly earnings enhancing in the current financial year. Cambridge’s commercial manager Peter Butterfield has also been appointed to the Alliance Pharma board.

The deal is worth between £14.3m and £16.4m, plus an additional £1.4m for Cambridge’s product inventory.

Back in January, Alliance said it expected to report turnover for the full year to 31 December 2009 of approximately £31 million, an increase of approximately 42% on the previous year.

Shares in Alliance have performed very well over the past six months as the stock’s value almost doubled from below 20 pence to the current 35 pence.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.